Boston Scientific Corporation (NYSE: BSX) is scheduled to report second-quarter 2024 results on Jul 24, before the opening bell. In the last reported quarter, the company's earnings per share of 56 cents exceeded the Zacks Consensus Estimate by 9.8%. BSX's bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.49%, on average. Q2 Estimates The Zacks Consensus Estimate for second-quarter total revenues is pegged at $4.02 billion, suggesting an improvement of 11.7% from the prior-year quarter's reported number. The consensus mark for adjusted earnings stands at 58 cents per share, implying a 9.4% rise from the year-ago quarter's reported figure. For the second quarter of 2024, the company projected revenue growth in the range of approximately 10.5-12.5% on a reported basis (an increase of 10-12% organically). Adjusted earnings are expected in the range of 57-59 cents per share. Estimate Revision Trend Ahead of Earnings The Zacks Consensus Estimate for Boston Scientific's second-quarter earnings has remained unchanged at 58 cents per share in the past 60 days. Let's briefly look at how things have progressed for the MedTech major leading up to this announcement. Factors at Play With U.S. hospital visits being on the rise through the second-quarter months of 2024, Boston Scientific, with its innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, looks well-positioned to report decent sales results for this period. However, the rate of growth is expected to have remained sluggish amid a challenging supply environment in limited geographies. Further, the business is expected to have faced the hurdle of surging labor and raw material costs, as well as healthcare staffing shortages, which might have weighed on the bottom line in the second quarter. On a geographic basis, despite all macroeconomic headwinds, the company registered strong growth in every geographic region in the last reported quarter, with core business units gaining or maintaining market share. However, with global staffing issues and the supply chain issue still remaining prominent, the international business of BSX is once again expected to have been partially hurt in the second quarter. The company is expected to have registered strong growth in the Asia Pacific, led by strength in China and Japan. Growth in Japan is expected to have been fueled by new products, most notably AGENT drug-coated balloon (DCB), Rezum, Access solutions products, POLARx FIT and ...